1.
Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
Kumar, S, Prajapati, KS, Singh, AK, Kushwaha, PP, Shuaib, M, Gupta, S
Cancer letters. 2021;:15-22
Abstract
The human genome transcribe an array of RNAs that do not encode proteins and may act as mediators in the regulation of gene expression. Long non-coding RNAs (lncRNAs) are a group of non-coding RNAs consisting of more than 200 nucleotides of RNA transcripts that play important role in tumor development. Numerous lncRNAs have been characterized as functional transcripts associated with several biological processes and pathologic stages. Although the biological function and molecular mechanisms of lncRNAs remains to be explored, recent studies demonstrate aberrant expression of several lncRNAs linked with various human cancers. The present review summarizes the current knowledge of lncRNA expression patterns and mechanisms that contribute to carcinogenesis. In particular, we focus on lncRNAs regulating androgen receptor signaling pathways in prostate and breast cancer subtype having prognostic and therapeutic implications.
2.
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
Gupta, S, Mauer, AM, Ryan, CW, Taber, DA, Samuels, BL, Fleming, GF, ,
American journal of clinical oncology. 2005;(1):65-9
Abstract
The incidence of breast cancer increases with age. This trial evaluated the efficacy and safety of oral UFT (ftorafur plus uracil) plus leucovorin in elderly patients with advanced breast cancer. Eligibility criteria included age > or =65 years, locally advanced or metastatic breast cancer, < or =1 prior chemotherapy regimens in the setting of metastatic disease, performance status 0-2, and adequate end-organ function. UFT at 300 mg/m2 per day as 2 divided doses and 30 mg leucovorin with each dose were administered orally daily for 21 days, followed by a 7-day rest period. Ten patients were accrued. Six patients received treatment in their first relapse and 3 in their second. One patient was chemotherapy-naive. The dose-limiting toxicity was diarrhea with grade 3 or 4 diarrhea occurring more often in the oldest patients (1 of 6 patients between 65 and 69 vs. 3 of 4 patients > or =70 years old). Protocol treatment was discontinued in 2 patients (ages 78 and 83) secondary to severe gastrointestinal toxicity. One patient achieved a partial response. Although UFT/leucovorin had efficacy in 1 patient, toxicity in the patients over 70 years of age was increased. Careful evaluation of anticancer drug toxicity in very elderly patients is important as our population ages.
3.
Experimental and theoretical investigation of fluorescence photobleaching and recovery in human breast tissue and tissue phantoms.
Gupta, S, Bhawna, , Goswami, P, Agarwal, A, Pradhan, A
Applied optics. 2004;(5):1044-52
Abstract
Photobleaching and recovery of 488-nm excited fluorescence from resected human breast tissue samples have been studied. Profiles of photobleaching decay were seen to be faster in cancerous tissue than in those of the normal tissue. The reverse behavior was observed in profiles of recovery after photobleaching. A theoretical model based on one-dimensional diffusion theory has been developed to provide insight into the phenomena of fluorescence during photobleaching and recovery in a multiply scattering medium such as tissue. To understand photobleaching and recovery with the help of this theoretical model, we carried out experiments with model media that were prepared with authentic fluorophores, scatterers, and absorbers. The results of these studies suggest that the fluorescence photobleaching profiles are affected more by the absorption than by the scattering properties of a turbid medium such as tissue. In contrast, the scattering properties of the medium are found to affect the fluorescence recovery profiles to a greater extent. These observations could be related to the observed difference in fluorescence photobleaching and recovery profiles of normal and cancerous breast tissues.